Long-term follow up: Ad hoc exploratory analysis with a median follow-up of 54 months
Nearly 5 years median overall survival for first-line premenopausal patients1,2
Hazard ratios are based on stratified Cox model.
At a median follow-up of 35 months
Superiority was established for overall survival in the first-line intent to treat (ITT) population
P=0.00973 (HR=0.71 [95% CI: 0.54-0.95])3
- In the subgroup of patients who received tamoxifen, an increased risk for QT prolongation was observed. KISQALI is not indicated for concomitant use with tamoxifen4
- mPFS (primary analysis): 23.8 months (95% CI: 19.2-NR) for KISQALI + ET vs 13.0 months for placebo + ET (95% CI: 11.0-16.4); HR=0.55 (95% CI: 0.44-0.69); P<0.00014
- Goserelin was used for ovarian suppression5
Yen-Shen Lu, MD
National Taiwan University Hospital
Taipei, Taiwan
Dr Lu provides an expert perspective on the updated ad hoc exploratory analysis for MONALEESA-7.
Michelino De Laurentiis, MD, PhD
National Cancer Institute
Naples, Italy
Hear Dr De Laurentiis discuss results from the updated ad hoc exploratory OS analysis.